UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
March 9, 2004
---------------------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
---------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
-------- --------- ----------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
---------------------------------------------------------------
(Address of principal executive offices)
(201) 750-2646
---------------------
(Registrant's telephone number, including area code)
Item 5. OTHER EVENTS AND REGULATION FD DISCLOSURE
The Registrant issued on March 9, 2004, a press release announcing that
it's Board of Directors has authorized an extension of the expiration date of
June 30, 2004 of the Registrant's Class B Warrants to coincide with the November
30, 2005 expiration of the Registrant's Class C Warrants. The exercise price of
the Class B Warrants will remain at $5.00 per share.
A copy of Registrant's press release is attached as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1. Press Release, dated March 9, 2004
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: March 9, 2004
ELITE PHARMACEUTICALS, INC.
By: /s/ BERNARD BERK
---------------------------------
Name: Bernard Berk
Title: Chief Executive Officer